Search results for "ENZYME"

showing 10 items of 3924 documents

Reactions of Flavonoids with o‑Quinones Interfere with the Spectrophotometric Assay of Tyrosinase Activity

2016

Flavonoids are important food components with antioxidant properties and many of them have been described as tyrosinase inhibitors. Oxidation of quercetin, kaempferol, morin, catechin, and naringenin by mushroom tyrosinase and their influence on the oxidation of l-dopa and l-tyrosine was studied. Reaction rates measured spectrophotometrically and by oxygen consumption differed substantially. All tested flavonoids reacted with 4-tert-butyl-o-benzoquinone and/or 4-methyl-o-benzoquinone, although at different rates. These reactions generated products whose UV-vis spectra either overlapped or did not overlap with the spectrum of dopachrome. They therefore strongly influence the kinetic analysis…

0301 basic medicineNaringenino-quinoneAntioxidantAgaricusTyrosinasemedicine.medical_treatmentMorintyrosinase01 natural sciencesFungal Proteins03 medical and health scienceschemistry.chemical_compoundBenzoquinonesmedicineOrganic chemistryenzymatic assay interferenceEnzyme AssaysCatecholMonophenol Monooxygenase010401 analytical chemistryfood and beveragesCatechinGeneral Chemistrycatechol0104 chemical sciencesKinetics030104 developmental biologychemistrySpectrophotometryflavonoidsDopachromeredox exchangeGeneral Agricultural and Biological SciencesKaempferolOxidation-ReductionNuclear chemistryJournal of Agricultural and Food Chemistry
researchProduct

Levosimendan protects human hepatocytes from ischemia-reperfusion injury.

2017

Background Ischemia-reperfusion injury (IRI) is a major challenge in liver transplantation. The mitochondrial pathway plays a pivotal role in hepatic IRI. Levosimendan, a calcium channel sensitizer, was shown to attenuate apoptosis after IRI in animal livers. The aim of this study was to investigate the effect of levosimendan on apoptosis in human hepatocytes. Methods Primary human hepatocytes were either exposed to hypoxia or cultured under normoxic conditions. After the hypoxic phase, reoxygenation was implemented and cells were treated with different concentrations of levosimendan (10ng/ml, 100ng/ml, 1000ng/ml). The overall metabolic activity of the cells was measured using 3-(4,5-dimeth…

0301 basic medicineNecrosisCritical Care and Emergency Medicinelcsh:MedicineApoptosis030204 cardiovascular system & hematologyBiochemistry0302 clinical medicineAnimal CellsMedicine and Health SciencesEnzyme assaysColorimetric assayslcsh:ScienceBioassays and physiological analysisCells CulturedEnergy-Producing Organellesbcl-2-Associated X ProteinMultidisciplinaryMTT assaybiologyCell DeathMitochondriaPyridazinesLiverCell ProcessesReperfusion Injurymedicine.symptomCellular TypesAnatomyCellular Structures and Organellesmedicine.drugResearch Articlemedicine.medical_specialtyCell PhysiologyIschemiaCardiologySurgical and Invasive Medical ProceduresBioenergetics03 medical and health sciencesDigestive System ProceduresBcl-2-associated X proteinInternal medicinemedicineHumansMTT assayddc:610SimendanHeart FailureTransplantationbusiness.industrylcsh:RHydrazonesBiology and Life SciencesLevosimendanCell BiologyOrgan TransplantationHypoxia (medical)medicine.diseaseLiver TransplantationCell MetabolismResearch and analysis methods030104 developmental biologyEndocrinologyApoptosisReperfusionBiochemical analysisbiology.proteinHepatocyteslcsh:QbusinessReperfusion injuryPloS one
researchProduct

Anisakis sensitization in different population groups and public health impact. A systematic review

2018

Anisakis simplex spp. sensitization rates have increased worldwide, with a significant impact on health-care systems. To date, no clear-cut diagnostic criteria and laboratory algorithm have been established, so anisakiasis still represents an under-reported health problem whose clinical manifestations, when present, mimic the much more common allergic and digestive disorders. Aim of the study was to systematically review the available literature on the prevalence of sensitization against Anisakis in the general population and in specific population groups, taking into account the impact of the different available diagnostic techniques on the epidemiological data. Following the Preferred Rep…

0301 basic medicineNematodaUrticarialcsh:MedicineSettore MED/42 - Igiene Generale E ApplicataAnisakisGeographical locations0302 clinical medicineAllergiesEpidemiologyMedicine and Health SciencesantibodiesEnzyme-Linked Immunoassayslcsh:SciencehumanshelminthSensitizationeducation.field_of_studyMultidisciplinaryAllergic DiseasesbiologyShellfish allergyEukaryotaanimals; anisakis; antibodies helminth; enzyme-linked immunosorbent assay; humans; hypersensitivity; occupational exposureClinical Laboratory SciencesEuropeanimalsClinical Laboratoriesmedicine.anatomical_structureSystematic reviewhypersensitivityResearch Articlemedicine.medical_specialtyImmunologyImmunoblotting030231 tropical medicinePopulationFood AllergiesAntibodies HelminthMolecular Probe TechniquesDermatologyResearch and Analysis Methods03 medical and health sciencesDiagnostic MedicineEnvironmental healthmedicineEuropean UnionImmunoassaysMolecular Biology TechniqueseducationMolecular BiologyBiochemistry Genetics and Molecular Biology (all)business.industryPublic healthlcsh:RAnisakis simplexOrganismsBiology and Life Sciencesoccupational exposureanisakismedicine.diseasebiology.organism_classificationInvertebrates030104 developmental biologyAgricultural and Biological Sciences (all)SpainImmunologic TechniquesClinical Immunologylcsh:Qenzyme-linked immunosorbent assayClinical MedicinePeople and placesbusiness
researchProduct

Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition.

2020

PURPOSE Children with pediatric gliomas harboring a BRAF V600E mutation have poor outcomes with current chemoradiotherapy strategies. Our aim was to study the role of targeted BRAF inhibition in these tumors. PATIENTS AND METHODS We collected clinical, imaging, molecular, and outcome information from patients with BRAF V600E–mutated glioma treated with BRAF inhibition across 29 centers from multiple countries. RESULTS Sixty-seven patients were treated with BRAF inhibition (pediatric low-grade gliomas [PLGGs], n = 56; pediatric high-grade gliomas [PHGGs], n = 11) for up to 5.6 years. Objective responses were observed in 80% of PLGGs, compared with 28% observed with conventional chemotherapy …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyHematologyendocrine system diseasesbusiness.industrydigestive system diseases3. Good healthBRAF V600E03 medical and health sciencesenzymes and coenzymes (carbohydrates)030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineMutation (genetic algorithm)Original Reportsmedicinebusinessskin and connective tissue diseasesneoplasmsChemoradiotherapyJCO precision oncology
researchProduct

miR‐200c and phospho‐AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis

2016

Lung metastasis is the major cause of death in osteosarcoma patients. However, molecular mechanisms underlying this metastasis remain poorly understood. To identify key molecules related with pulmonary metastasis of pediatric osteosarcomas, we analyzed high-throughput miRNA expression in a cohort of 11 primary tumors and 15 lung metastases. Results were further validated with an independent cohort of 10 primary tumors and 6 metastases. In parallel, we performed immunohistochemical analysis of activated signaling pathways in 36 primary osteosarcomas. Only phospho-AKT associated with lower overall survival in primary tumors, supporting its role in osteosarcoma progression. CTNNB1 expression a…

0301 basic medicineOncologyMaleCancer ResearchmiR‐200cLung NeoplasmsCDH1MetastasisCohort Studies0302 clinical medicineCell MovementPhospho‐AKTPhosphorylationChildOsteosarcomabiologyGeneral MedicineArticlesCadherinsPrognosisPrimary tumorGene Expression Regulation Neoplasticmedicine.anatomical_structureLung metastasisOncology030220 oncology & carcinogenesisDisease ProgressionMolecular MedicineOsteosarcomaFemaleSignal Transductionmedicine.medical_specialtyAdolescentMesenchymal to epithelial transitionArticle03 medical and health sciencesYoung AdultAntigens CDInternal medicineCell Line TumormicroRNAGeneticsmedicineBiomarkers TumorHumansEpithelial–mesenchymal transitionCell ProliferationLungGene Expression ProfilingReproducibility of ResultsEpithelial CellsPediatric osteosarcomamedicine.diseaseSurvival AnalysisEnzyme ActivationMicroRNAs030104 developmental biologyTumor progressionbiology.proteinProto-Oncogene Proteins c-aktMolecular Oncology
researchProduct

Schlafen-11 (SLFN11): a step forward towards personalized medicine in small-cell lung cancer?

2018

Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). Patients and Methods A total of 104 patients with recurrent SCLC were randomly assigned 1:1 to oral veliparib or placebo 40 mg twice daily, days 1 to 7, and oral TMZ 150 to 200 mg/m

0301 basic medicineOncologyMaleLung NeoplasmsDNA Mutational AnalysisPoly (ADP-Ribose) Polymerase-1Placebos0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsPromoter Regions GeneticDNA Modification MethylasesAged 80 and overStandard treatmentNuclear ProteinsMiddle AgedNeoplastic Cells CirculatingImmunohistochemistryhumanitiesEditorialOncology030220 oncology & carcinogenesisFemaleNon small cellAdultmedicine.medical_specialtyMEDLINEAggressive disease03 medical and health sciencesText miningDouble-Blind MethodInternal medicinemedicineBiomarkers TumorTemozolomideHumansLung cancerneoplasmsAntineoplastic Agents AlkylatingAgedbusiness.industryTumor Suppressor ProteinsDNA Methylationmedicine.diseaseSmall Cell Lung Carcinomarespiratory tract diseases030104 developmental biologyDNA Repair EnzymesBenzimidazolesPersonalized medicinebusiness
researchProduct

A pilot study of circulating microRNAs as potential biomarkers of Fabry disease

2018

Patients suffering from Fabry disease (FD), a lysosomal storage disorder, show a broad range of symptoms and the diagnosis followed by the therapeutic decision remains a great challenge. The biomarkers available today have not proven to be useful for predicting the evolution of the disease and for assessing response to therapy in many patients. Here, we used high-throughput microRNA profiling methodology to identify a specific circulating microRNA profile in FD patients. We discovered a pattern of 10 microRNAs able to identify FD patients when compared to healthy controls. Notably, two of these: the miR199a-5p and the miR-126-3p are able to discriminate FDs from the control subjects with le…

0301 basic medicineOncologymedicine.medical_specialtyDisease030204 cardiovascular system & hematologyLeft ventricular hypertrophy03 medical and health sciences0302 clinical medicineSettore BIO/13 - Biologia ApplicataInternal medicinemedicinePathologyEndothelial dysfunctionPathologicalFabry diseasebusiness.industryMicroRNAEnzyme replacement therapyBiomarkermedicine.diseaseFabry diseaseBiomarker; ERT; Fabry disease; LVH; MicroRNA; Pathology; OncologyCirculating MicroRNALVH030104 developmental biologyOncologyBiomarker (medicine)ERTbusiness
researchProduct

Comparative Evaluation of role of Lysyl oxidase gene (LOXG473A) expression in pathogenesis and malignant transformation of Oral Submucous Fibrosis.

2019

Background Identification and comparison of gene expression of Lysyl oxidase (LOX) in oral submucous fibrosis and controls and to determine its role in Pathogenesis of Oral submucous fibrosis. Material and Methods Of total sample size (n=127), the whole blood sample were collected from case and control group in citrate vial. It is centrifused and stored at -800C. We collected and isolated RNA from blood of case group (n=127) and age and sex matched control group (n=127) recruited on the basis of inclusion criteria. The cDNA was prepared for 127 samples which were processed for gene expression of Lysyl oxidase (LOX) in relation to housekeeping genes (Beta actin and 18srRNA) and its role in p…

0301 basic medicineOral Medicine and Pathologyintegumentary systemResearchLysyl oxidaseBiologymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Molecular biologyMalignant transformationHousekeeping genePathogenesis03 medical and health sciencesenzymes and coenzymes (carbohydrates)030104 developmental biology0302 clinical medicineOral submucous fibrosis030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASGene expressionmedicineBeta-actinGeneral DentistryGeneJournal of clinical and experimental dentistry
researchProduct

Genomic and functional gene studies suggest a key role of beta-carotene oxygenase 1 like (bco1l) gene in salmon flesh color

2019

AbstractRed coloration of muscle tissue (flesh) is a unique trait in several salmonid genera, including Atlantic salmon. The color results from dietary carotenoids deposited in the flesh, whereas the color intensity is affected both by diet and genetic components. Herein we report on a genome-wide association study (GWAS) to identify genetic variation underlying this trait. Two SNPs on ssa26 showed strong associations to the flesh color in salmon. Two genes known to be involved in carotenoid metabolism were located in this QTL- region: beta-carotene oxygenase 1 (bco1) and beta-carotene oxygenase 1 like (bco1l). To determine whether flesh color variation is caused by one, or both, of these g…

0301 basic medicineOxygenasegenetic structuresQuantitative Trait LociSalmo salarPopulationlcsh:MedicineGenome-wide association studySingle-nucleotide polymorphismQuantitative trait locusBiologyArticle03 medical and health sciencesstomatognathic systemGenetic variationAnimalsVDP::Landbruks- og Fiskerifag: 900::Fiskerifag: 920::Fiskehelse: 923lcsh:ScienceeducationCarotenoidGenebeta-Carotene 1515'-Monooxygenasechemistry.chemical_classificationGeneticseducation.field_of_studyMultidisciplinary030102 biochemistry & molecular biologyPigmentationEukaryoteFleshlcsh:Rfood and beveragesGenomicsbeta CaroteneEnzymes030104 developmental biologychemistrylcsh:QGenome-Wide Association Study
researchProduct

Propeptide glycosylation and galectin‐3 binding decrease proteolytic activation of human proMMP‐9/progelatinase B

2019

Matrix metalloproteinases (MMPs) are secreted as proenzymes, containing propeptides that interact with the catalytic zinc, thereby controlling MMP activation. The MMP‐9 propeptide is unique in the MMP family because of its post‐translational modification with an N‐linked oligosaccharide. ProMMP‐9 activation by MMP‐3 occurs stepwise by cleavage of the propeptide in an aminoterminal (pro‐AT) and carboxyterminal (pro‐CT) peptide. We chemically synthesized aglycosyl pro‐AT and pro‐CT and purified recombinant glycosylated pro‐ATS f−9. First, we report new cleavage sites in the MMP‐9 propeptide by MMP‐3 and neutrophil elastase. Additionally, we demonstrated with the use of western blot analysis a…

0301 basic medicinePNGase FN-linked glycosylationGlycosylationGlycosylationmatrix metalloproteinase‐9Galectin 3GalectinsProteolysisgalectin‐3Biochemistry03 medical and health scienceschemistry.chemical_compoundCongenital Disorders of Glycosylation0302 clinical medicineN-linked glycosylationmatrix metalloproteinase-9galectin-3medicineHumansZymographyAmino Acid SequenceProtein precursorMolecular BiologyN‐linked glycosylationEnzyme Precursorspropeptidemedicine.diagnostic_testbiologyBlood ProteinsOriginal ArticlesCell BiologyTrypsinEnzyme Activation030104 developmental biologyMatrix Metalloproteinase 9chemistryBiochemistryGelatinasesCase-Control Studiesproteolytic activation030220 oncology & carcinogenesisNeutrophil elastaseProteolysisbiology.proteinMatrix Metalloproteinase 3Original ArticleLeukocyte Elastasemedicine.drug
researchProduct